8-K
filed June 2, 2025, 7:59 PM ET
CIK 0001293971
M&A
confidence high
sentiment positive
materiality 1.00
Carlyle and SK Capital complete acquisition of bluebird bio; stock delisted, new CEO David Meek
bluebird bio, Inc.
- Acquisition closed June 2, 2025; shareholders could elect $3.00 + one CVR per share, or $5.00 all-cash per share.
- Approximately 59.8% of outstanding shares validly tendered before expiration; all conditions satisfied.
- David Meek appointed CEO; prior CEO Andrew Obenshain and other executives terminated, eligible for severance.
- Stock halted and delisted from Nasdaq; company will file Form 15 to terminate registration.
- Carlyle and SK Capital provide primary capital to support scaled access to gene therapies for sickle cell, β-thalassemia, and CALD.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Najoh Tita-Reid departed as Director at bluebird bio, Inc..
- Action
- ceased to be a member
- Role
- Director
Exact text from the filing
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Andrew Obenshain departed as Director at bluebird bio, Inc..
- Action
- ceased to be a member
- Role
- Director
Exact text from the filing
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mark Vachon departed as Director at bluebird bio, Inc..
- Action
- ceased to be a member
- Role
- Director
Exact text from the filing
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard Paulson departed as Director at bluebird bio, Inc..
- Action
- ceased to be a member
- Role
- Director
Exact text from the filing
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.85
Joseph Vittiglio was terminated as other_named_officer at bluebird bio, Inc..
- Action
- terminated
Exact text from the filing
the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Charlotte Jones-Burton departed as Director at bluebird bio, Inc..
- Action
- ceased to be a member
- Role
- Director
Exact text from the filing
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John O. Agwunobi departed as Director at bluebird bio, Inc..
- Action
- ceased to be a member
- Role
- Director
Exact text from the filing
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nick Leschly departed as Director at bluebird bio, Inc..
- Action
- ceased to be a member
- Role
- Director
Exact text from the filing
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.85
Andrew Obenshain was terminated as other_named_officer at bluebird bio, Inc..
- Action
- terminated
Exact text from the filing
the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mike Cloonan departed as Director at bluebird bio, Inc..
- Action
- ceased to be a member
- Role
- Director
Exact text from the filing
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lis Leiderman departed as Director at bluebird bio, Inc..
- Action
- ceased to be a member
- Role
- Director
Exact text from the filing
each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.85
O. James Sterling was terminated as other_named_officer at bluebird bio, Inc..
- Action
- terminated
Exact text from the filing
the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
bluebird bio, Inc.: Certificate of incorporation amended and restated in its entirety (effective 2025-06-02).
- Change
- charter amendment
- Effective
- 2025-06-02
Exact text from the filing
on June 2, 2025, the Company's certificate of incorporation and bylaws were each amended and restated in their entirety and, as so amended and restated, became the certificate of incorporation and bylaws of the Surviving Corporation.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
bluebird bio, Inc.: Bylaws amended and restated in their entirety (effective 2025-06-02).
- Change
- bylaw amendment
- Effective
- 2025-06-02
Exact text from the filing
on June 2, 2025, the Company's certificate of incorporation and bylaws were each amended and restated in their entirety and, as so amended and restated, became the certificate of incorporation and bylaws of the Surviving Corporation.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.